Skip to content
Comparison

GHRP-6 vs GHRP-1

GHRP-6 and GHRP-1 are commonly compared for first- vs later-generation GH secretagogue options. GHRP-6 is usually favored for stronger practical GH/appetite signal in modern use, while GHRP-1 is often preferred for historical class prototype comparator. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For first- vs later-generation GH secretagogue options, the better choice depends on your primary endpoint. GHRP-6 is stronger when the priority is modern protocol relevance. GHRP-1 is stronger when the priority is legacy mechanistic benchmarking. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaGHRP-6GHRP-1
Primary mechanismPotent ghrelin-receptor agonist growth-hormone secretagogueFirst-generation growth-hormone releasing peptide
Strongest clinical signalStrong GH pulse and strong appetite stimulationProof-of-concept GH secretagogue activity
Typical dosing context100-300 mcg 2-3 times dailyResearch protocols vary; typically microgram injection ranges
AdministrationSubcutaneous injectionSubcutaneous injection
Evidence quality gradeModerate mechanistic data, limited modern outcomes trialsOlder, limited clinical evidence base
Regulatory statusPreclinical/research-use peptideResearch-use only
Side-effect burdenHigher hunger, cortisol, and prolactin signal than selective optionsData depth and modern safety characterization are limited
Cost/access contextGenerally affordable in peptide marketsLow-to-moderate research-market pricing
Best candidate profileBulking phases where appetite stimulation is usefulHistorical comparator for GH secretagogue class effects
Main limitationSide-effect burden limits broad long-term useOutperformed by newer GH-secretagogue options
Best use case in this comparisonmodern protocol relevancelegacy mechanistic benchmarking

When to Choose Each

Choose GHRP-6

Best for modern protocol relevance.

Choose GHRP-1

Best for legacy mechanistic benchmarking.

Verdict

If the main goal is modern protocol relevance, GHRP-6 is usually the better first-line choice. If the main goal is legacy mechanistic benchmarking, GHRP-1 is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Growth hormone (GH)-releasing peptide-6 stimulates GH release and food intake in the rat (1997) — PubMed
  2. A synthetic fragment of human growth hormone (AOD9604) that reduces body fat in obese Zucker rats (2001) — PubMed
  3. Cytoprotective effects of growth hormone-releasing peptide-6 on gastric mucosal injury (2000) — PubMed
  4. The GH secretagogue GHRP-6: neuroprotective effects in a global cerebral ischemia model (2007) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for first- vs later-generation GH secretagogue options — GHRP-6 or GHRP-1?
GHRP-6 is graded as moderate mechanistic data, limited modern outcomes trials evidence in this context, while GHRP-1 is graded as older, limited clinical evidence base. In practice, strength depends on whether you prioritize modern protocol relevance or legacy mechanistic benchmarking. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can GHRP-6 and GHRP-1 be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next